BEAT

HeartBeam, Inc.

NasdaqAdd to watchlist

Healthcare · Health Information Services

$0.42

+$0.01+2.62%

Delayed · 2026-09-17T20:00:00.000Z · marketstack

2 open-market sales on file ($1.08M), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$0.42

−$0.06−13.14%over 1M

Session

Day range74% of range

$0.41$0.42

Fundamentals

Visualize fundamentals and more

Market cap: 22.15M
P/E ratio: -

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 2
dropped: 2
re-drafted: 8

Out of 135 passages in this year’s Item 1A.

New this year

As described in Note 2 of our accompanying audited financial statements, we believe that our existing working capital is insufficient to fund operations for the next twelve months following the issuance of the annual report. These factors raise substantial …

3 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Russia and Ukraine
Export controls
Tax
Going concern

And 13 more.

FDA approval
Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 17, 2026 · the last close

HeartBeam, Inc. investor relations

What BEAT has filed with the SEC. This is not HeartBeam, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like HeartBeam, Inc.

Also filed under Health Information Services, ranked by how closely they sit beside BEAT.

VEEVVeeva Systems Inc.compare with BEAT
TXG10x Genomics, Inc.compare with BEAT
GEHCGE HealthCare Technologies Inc.

WGSGeneDx Holdings Corp.compare with BEAT

HQYHEALTHEQUITY, Inc.compare with BEAT

DOCSDoximity, Inc.compare with BEAT

Ask about HeartBeam, Inc.

The assistant answers from what BEAT has actually filed: 6 annual reports filed with the SEC, 18 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from BEAT's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of HeartBeam, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with HeartBeam, Inc.

Be told the moment a BEAT insider trades
Put HeartBeam, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
HeartBeam, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about HeartBeam, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 2
dropped: 2
re-drafted: 8

Out of 135 passages in this year’s Item 1A.

New this year

As described in Note 2 of our accompanying audited financial statements, we believe that our existing working capital is insufficient to fund operations for the next twelve months following the issuance of the annual report. These factors raise substantial …

3 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

16 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Russia and Ukraine
Export controls
Tax
Going concern

And 13 more.

FDA approval
Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add